Another Vaccine for the Pandemic Arsenal

The Novavax COVID-19 vaccine has shown high efficacy—90.4% overall—against the disease in its Phase 3 trial, the company announced today
The not-yet-peer-reviewed results:

  • 93% efficacy against predominantly circulating variants of concern/interest
  • 91% efficacy in high-risk populations
  • 100% efficacy against variants “not considered variants of concern/interest”

The study enrolled nearly 30,000 participants in nearly 120 sites in the US and Mexico to test the recombinant nanoparticle protein-based COVID-19 vaccine, named NVX-CoV2373.
Novavax’s to-do list:

  • Submit the full trial data for publication in a peer-reviewed journal
  • File with drug regulators including the FDA for regulatory authorization in the third quarter
  • Produce 100 million doses/month by the end of the third quarter, up to 150 million/month by the end of 2021.


The Quote: “It’s really very impressive,” NIAID director Anthony S. Fauci, told The Washington Post: “It’s very important for the world’s population to have, yet again, another highly efficacious vaccine that looks in its trial to have a good safety profile.”

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top